Stoke therapeutics stock.

Nov 29, 2023 · Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting. BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit... Discover historical prices for STOK stock on Yahoo Finance. View daily, weekly or monthly format back to when Stoke Therapeutics, Inc. stock was issued.STOK Earnings Date and Information. Stoke Therapeutics last posted its quarterly earnings data on November 7th, 2023. The reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.10. The business earned $3.31 million during the quarter, compared to analyst estimates of $3.83 million.Find the latest Outlook Therapeutics, Inc. (OTLK) stock quote, history, news and other vital information to help you with your stock trading and investing.Jun 2, 2023 · Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently up 8.66% so far this month. During the month of June, Stoke Therapeutics Inc’s stock price has reached a high of $12.20 and a low of $10.69. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08. The biotechnology company had revenue of $30 million for the quarter, compared to the …Jul 25, 2023 · Stoke Therapeutics ( NASDAQ: STOK) lost ~30% in value on Tuesday after the company announced new data from its Phase 1/2a Studies for the antisense oligonucleotide STK-001 targeted at patients ... Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 11.9% so far this month. During the month of August, Stoke Therapeutics Inc’s stock price has reached a high of $6.58 and a low of $5.40. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $5.79. Year to date ...

Find the latest Alaunos Therapeutics, Inc. (TCRT) stock quote, history, news and other vital information to help you with your stock trading and investing.Moderna, Inc. (NASDAQ:MRNA) issued its earnings results on Thursday, November, 2nd. The company reported ($1.39) EPS for the quarter, beating the consensus estimate of ($2.01) by $0.62. The business earned $1.83 billion during the quarter, compared to analysts' expectations of $1.37 billion.

Upcoming events on Stoke Therapeutics, Inc. 2023-12-02 12:00 pm American Epilepsy Society Meeting - Poster No:1.276Find the latest AN2 Therapeutics, Inc. (ANTX) stock quote, history, news and other vital information to help you with your stock trading and investing.BEDFORD - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company's work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1 - 5, in ...Mar 6, 2023 · Stoke Therapeutics, Inc. (STOK Quick Quote STOK - Free Report) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0 ... Beam Therapeutics ( BEAM 0.68%) recently signed a major research deal with Pfizer ( PFE 0.59%) that could be worth up to $1.35 billion, and hardly anyone seemed to notice. This was clearly great ...

Structure Therapeutics started at outperform with $40 stock price target at BMO Capital. Feb. 28, 2023 at 9:46 a.m. ET by Tomi Kilgore.

Find the latest Intellia Therapeutics, Inc. (NTLA) stock quote, history, news and other vital information to help you with your stock trading and investing.

BEDFORD - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by …Find the latest Aclaris Therapeutics, Inc. (ACRS) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Cognition Therapeutics, Inc. (CGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Eric Rojas Vice President, Investor Relations [email protected] 617-312-2754 Source: Stoke Therapeutics, Inc.Nov 29, 2022 · BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 29, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Company’s work in Dravet syndrome have been accepted ... 4 equities research analysts have issued 1-year target prices for Viracta Therapeutics' shares. Their VIRX share price targets range from $5.00 to $16.00. On average, they predict the company's share price to reach $9.25 in the next twelve months. This suggests a possible upside of 1,645.3% from the stock's current price.

STOK Stoke Therapeutics Inc Form SC TO-I/A - Tender offer statement by Issuer: [Amend]Aug 16, 2023 · Is Stoke Therapeutics stock a buy? Stoke is a rare opportunity to invest in a cutting-edge biotech company that could revolutionize the treatment of genetic diseases. With a limited yet high-value ... Wedbush Lowers Stoke Therapeutics' Price Target to $13 From $18, Shifts STK-001 Launch Timing; Retains Outperform Rating. Aug. 08. MT. Stoke Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023. Granahan Investment Management LLC lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 11.7% during the 2nd quarter, according to the company in its most recent ...Nov 8, 2023 · Stoke Therapeutics Inc (STOK) has experienced a 27.30% rise in stock performance for the past week, with a 28.31% rise in the past month, and a -13.08% drop in the past quarter. The volatility ratio for the week is 8.16%, and the volatility levels for the past 30 days are at 6.66% for STOK. The simple moving average for the past 20 days is 25. ... 11 Nov 2023 ... Since July 2023, shares of Stoke's common stock have declined in value from a trading price of over $10.00 per share to a current trading price ...

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues …Stoke Therapeutics Inc (NASDAQ: STOK) has seen a decline in its stock price by -9.54 in relation to its previous close of 4.61. However, the company has experienced a -7.95% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2023-09-10 that Stoke Therapeutics (STOK) stock is down 40% after failing to meet ...

Find the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing. Stoke Therapeutics (NASDAQ:STOK) Second Quarter 2023 ResultsKey Financial Results. Net loss: US$30.7m (loss widened by 24% from 2Q 2022). US$0.69 loss per share (further deteriorated from US$0.63 ...Find the latest Tenax Therapeutics, Inc. (TENX) stock quote, history, news and other vital information to help you with your stock trading and investing.BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2021-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from five presentations related to the ongoing clinical development of STK-001 ...Stoke Therapeutics (STOK) (Delayed Data from NSDQ) $3.79 USD -0.06 (-1.56%) Updated Nov 30, 2023 04:00 PM ET After-Market: $3.77 -0.02 (-0.53%) 5:10 PM …According to the issued ratings of 8 analysts in the last year, the consensus rating for Stoke Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for STOK. The average twelve-month price prediction for Stoke Therapeutics is $21.00 with a high price target of $35.00 and a low price target of $12.00.Stoke Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.67. See the top stocks recommended by analysts >> The company has a one-year high of $26.60 and a ...Stock analysis for Stoke Therapeutics Inc (STOK:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.What is the target price for Stoke Therapeutics (STOK) stock? A. The latest price target for Stoke Therapeutics ( NASDAQ: STOK) was reported by Needham on Tuesday, November 7, 2023. The analyst ...Get a real-time Stoke Therapeutics, Inc. (STOK) stock price quote with breaking news, financials, statistics, charts and more.

Structure Therapeutics started at outperform with $40 stock price target at BMO Capital. Feb. 28, 2023 at 9:46 a.m. ET by Tomi Kilgore.

Find the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing.Overview Stock Screener Earnings Calendar Sectors Nasdaq | STOK U.S.: Nasdaq Stoke Therapeutics Inc. Watch NEW Set a price target alert After Hours Last …Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for ...In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000. Following this sale, Ticho now owns 25,895 shares in the company with a valuation of $274,487. This transaction was disclosed through a …Stoke Therapeutics (NASDAQ:STOK), a leading biotechnology company, has experienced significant fluctuations in its stock price over the past year. As of July 28, 2023, shares of STOK stock opened at a modest …Aug 8, 2022 · Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? 1800 El Camino Real, Suite D Menlo Park, CA 94027 650-331-9090. [email protected]. Investor & Media Inquiries [email protected]. [email protected]. [email protected]. The Investor Relations website contains information about AN2 Therapeutics, Inc's business for stockholders, …Stoke Therapeutics is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based ...Dec 1, 2023 · Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low. Stoke Therapeutics ( NASDAQ: STOK) lost ~30% in value on Tuesday after the company announced new data from its Phase 1/2a Studies for the antisense oligonucleotide STK-001 targeted at patients ...

Find the latest Context Therapeutics Inc. (CNTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics Inc’s ( STOK) price is currently down 10.24% so far this month. During the month of March, Stoke Therapeutics Inc’s stock price has reached a high of $9.99 and a low of $7.22. Over the last year, Stoke Therapeutics Inc has hit prices as high as $24.97 and as low as $6.88. Year to date, Stoke Therapeutics Inc’s stock is ...Find the latest TG Therapeutics, Inc. (TGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 8, 2023 · Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG remains neutral on the stock and ... Instagram:https://instagram. ai trading platformhealth insurance companies in nj listbrokers to trade optionstarget fom (RTTNews) - Stoke Therapeutics, Inc. (STOK) Tuesday reported positive safety and efficacy data from two Phase 1/2a studies of its drug candidate STK-001 for the treatment of Dravet syndrome. gainers stock todaynasdaq pays Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Stoke Therapeutics Stock Price Chart Technical Analysis: Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and STOK is experiencing selling pressure, which indicates risk of future bearish movement. acb stocktwits Complete Stoke Therapeutics Inc. stock information by Barron's. View real-time STOK stock price and news, along with industry-best analysis. Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates. November 7, 2023 – STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat ...